Icariin (3-(5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy-7-(β-D-glucopyranosyloxy)chromen-4-one)

Icariin is a prenylated flavonoid glycoside derived from Epimedium (horny goat weed) that acts primarily as a phosphodiesterase type 5 (PDE5) inhibitor, increasing cyclic GMP levels to promote vasodilation and endothelial function. It also modulates estrogen receptors, Wnt/β-catenin signaling, and SIRT1 pathways, producing antioxidant, bone-protective, and cardioprotective effects documented extensively in preclinical models.

Origin & History

Icariin is a prenylated flavonol glycoside isolated primarily from plants in the genus Epimedium (Berberidaceae family), commonly known as horny goat weed or Yin Yang Huo. These perennial herbs grow on cliffs and wet lands at elevations of 200-3700 m from Japan to Algeria, and icariin is extracted from the herb tops or leaves for use in traditional Chinese medicine formulations.

Historical & Cultural Context

In traditional Chinese medicine, icariin-rich Epimedium (Ying Yang Huo or Herba Epimedii) has been used for over 1,000 years to treat coronary heart disease, impotence, osteoporosis, rheumatism, and as an aphrodisiac. Historical applications also include anti-aging and reproductive support.

Health Benefits

• Cardiovascular protection through PDE5 inhibition and endothelial function improvement (preclinical evidence only)
• Anti-atherosclerosis effects via reduced LDL-cholesterol and increased HDL-cholesterol (demonstrated in animal models)
• Antioxidant properties that reduce ROS-induced DNA damage and erythrocyte peroxidation (in vitro studies)
• Anti-inflammatory action through suppression of NF-κB, COX-2, and iNOS pathways (cell-based studies)
• Potential tissue regeneration support for chondrocytes and cardiomyocytes (preliminary cell studies)

How It Works

Icariin inhibits phosphodiesterase type 5 (PDE5), preventing the degradation of cyclic guanosine monophosphate (cGMP), which relaxes vascular smooth muscle and improves endothelial nitric oxide (NO) bioavailability. It activates the Wnt/β-catenin signaling pathway and upregulates RUNX2 and OPG expression to promote osteoblastogenesis while suppressing RANKL-driven osteoclast activity. Additionally, icariin scavenges reactive oxygen species (ROS), upregulates Nrf2-mediated antioxidant enzymes including superoxide dismutase (SOD) and catalase, and modulates ERα/ERβ estrogen receptor subtypes to exert phytoestrogenic effects.

Scientific Research

Current evidence for icariin is limited to preclinical studies, with no human clinical trials, RCTs, or meta-analyses identified in the research. Animal models demonstrate cardiovascular benefits including lipid modulation and anti-atherosclerotic effects, while in vitro studies support antioxidant and anti-inflammatory mechanisms.

Clinical Summary

The majority of icariin research consists of in vitro cell studies and rodent models, with very limited randomized controlled trials in humans. Animal studies using doses of 10–100 mg/kg/day have demonstrated reductions in LDL-cholesterol, increases in HDL-cholesterol, and improved bone mineral density in ovariectomized mouse models of osteoporosis. A small number of Chinese clinical trials involving postmenopausal women (n=60–120) reported modest improvements in bone turnover markers and lipid profiles, though methodological quality and trial registration vary considerably. Evidence for erectile function improvement in humans remains largely anecdotal or derived from small, poorly controlled studies, and no large-scale Phase III trials have confirmed efficacy or optimal dosing in any indication.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "carbohydrates": "Not applicable", "fats": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"icariin": "Primary bioactive compound", "concentration": "Varies depending on the source, typically found in concentrations ranging from 0.1% to 5% in Epimedium extracts"}, "bioavailability_notes": "Icariin's bioavailability is generally low due to poor water solubility and rapid metabolism. It may be enhanced through formulation strategies such as nanoparticle delivery systems."}

Preparation & Dosage

No clinically studied dosage ranges for human use are available from the current research. Icariin is typically consumed as part of Epimedium extracts, but specific standardization percentages or therapeutic doses have not been established in human studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginkgo biloba, L-arginine, Panax ginseng, Resveratrol, CoQ10

Safety & Interactions

Icariin is generally considered well-tolerated at typical supplemental doses (150–1000 mg/day of standardized Epimedium extract), but high doses may cause dry mouth, dizziness, nosebleed, or rapid heartbeat in sensitive individuals. Due to its PDE5-inhibitory activity, icariin may potentiate the hypotensive effects of nitrate medications and PDE5 inhibitor drugs such as sildenafil (Viagra), and concurrent use is contraindicated. Its phytoestrogenic activity raises theoretical concerns for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine cancer, or endometriosis, and it should be avoided during pregnancy and lactation due to insufficient safety data. Icariin may also interact with CYP3A4-metabolized drugs by moderately inhibiting this hepatic enzyme, potentially altering plasma concentrations of affected medications.